Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment

PURPOSE: Immunotherapy has recently been shown to improve outcomes for advanced PD-L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA approval of the first immune checkpoint inhibitor in combination with taxane chemotherapy. To further develop predictive bioma...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Autores principales: Deng, Jiehui, Thennavan, Aatish, Shah, Suhagi, Bagdatlioglu, Ece, Klar, Natalie, Heguy, Adriana, Marier, Christian, Meyn, Peter, Zhang, Yutong, Labbe, Kristen, Almonte, Christina, Krogsgaard, Michelle, Perou, Charles M., Wong, Kwok-Kin, Adams, Sylvia
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8170702/
https://ncbi.nlm.nih.gov/pubmed/32949350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05936-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares